Twist Bioscience Co. (NASDAQ:TWST) Shares Acquired by Trexquant Investment LP

Trexquant Investment LP raised its holdings in Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 7.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 168,227 shares of the company's stock after purchasing an additional 11,725 shares during the period. Trexquant Investment LP owned about 0.28% of Twist Bioscience worth $7,818,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Barclays PLC increased its holdings in Twist Bioscience by 214.8% in the 3rd quarter. Barclays PLC now owns 153,039 shares of the company's stock worth $6,913,000 after acquiring an additional 104,420 shares in the last quarter. FMR LLC boosted its holdings in Twist Bioscience by 6.0% in the 3rd quarter. FMR LLC now owns 218,561 shares of the company's stock worth $9,875,000 after buying an additional 12,327 shares during the last quarter. Avanza Fonder AB purchased a new stake in Twist Bioscience during the 4th quarter worth approximately $1,059,000. BNP Paribas Financial Markets raised its holdings in shares of Twist Bioscience by 128.1% during the third quarter. BNP Paribas Financial Markets now owns 38,032 shares of the company's stock valued at $1,718,000 after acquiring an additional 21,357 shares during the last quarter. Finally, Principal Financial Group Inc. lifted its position in shares of Twist Bioscience by 67.5% in the third quarter. Principal Financial Group Inc. now owns 205,864 shares of the company's stock valued at $9,301,000 after acquiring an additional 82,953 shares in the last quarter.

Twist Bioscience Trading Up 14.5 %

TWST stock traded up $5.09 during midday trading on Wednesday, hitting $40.27. 2,589,001 shares of the company's stock were exchanged, compared to its average volume of 972,930. Twist Bioscience Co. has a 1-year low of $27.41 and a 1-year high of $60.90. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. The stock has a market capitalization of $2.40 billion, a PE ratio of -11.91 and a beta of 2.34. The business has a 50-day simple moving average of $42.41 and a two-hundred day simple moving average of $44.78.

Remove Ads

Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.62) by $0.09. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The firm had revenue of $88.70 million during the quarter, compared to the consensus estimate of $86.96 million. During the same period last year, the company earned ($0.75) EPS. The company's quarterly revenue was up 24.1% on a year-over-year basis. On average, sell-side analysts predict that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on TWST shares. Robert W. Baird increased their price objective on Twist Bioscience from $48.00 to $54.00 and gave the company an "outperform" rating in a research note on Tuesday, February 4th. Barclays set a $58.00 price target on shares of Twist Bioscience and gave the stock an "overweight" rating in a research note on Monday, February 3rd. JPMorgan Chase & Co. upped their price objective on shares of Twist Bioscience from $35.00 to $40.00 and gave the company an "underweight" rating in a research note on Tuesday, February 4th. Scotiabank reissued an "outperform" rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. Finally, Guggenheim set a $50.00 price target on Twist Bioscience in a research report on Friday, March 28th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $54.10.

Insider Transactions at Twist Bioscience

In other Twist Bioscience news, CEO Emily M. Leproust sold 5,200 shares of the company's stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $49.35, for a total transaction of $256,620.00. Following the transaction, the chief executive officer now directly owns 667,318 shares in the company, valued at $32,932,143.30. This represents a 0.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Adam Laponis sold 5,886 shares of Twist Bioscience stock in a transaction on Friday, January 10th. The shares were sold at an average price of $43.26, for a total value of $254,628.36. Following the completion of the sale, the chief financial officer now directly owns 110,096 shares of the company's stock, valued at $4,762,752.96. The trade was a 5.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 28,682 shares of company stock worth $1,332,011. 3.01% of the stock is currently owned by insiders.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.